Search Results

Athersys, Inc., announced the pricing of its “reasonable best efforts” public offering of 10,937,500 shares of common stock at a purchase price of $0.32 per share.

Athersys, Inc. announced financial results for the three and nine months ended September 30, 2023 and provided a business update.

Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announces changes to its Board of Directors following the Company’s recent 2023 Annual Meeting of Stockholders.

Athersys, Inc., a regenerative medicine company developing MultiStem® cell therapy for critical care indications announced it has restructured its outstanding debt with a supplier.

Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announced the appointment of Neema Mayhugh, PhD to its Board of Directors.

Athersys, Inc., a cell therapy and regenerative medicine company developing MultiStem® for critical care indications, and Multipotent Adult Progenitor Cell technology for equine, canine, and feline health applications, announces the signing of a licensing agreement with Ardent Animal Health.

Athersys, Inc., a regenerative medicine company developing MultiStem® cell therapy for critical care indications, announced its participation in three upcoming conferences during the month of May.

Athersys, Inc. announces that Dr. Samuel Tingle, a surgeon and PhD candidate at Newcastle University in Newcastle upon Tyne, England, has received grant funding from the UK Research and Innovation’s Medical Research Council to explore the potential use of Athersys’ MultiStem cellular therapy during machine perfusion prior to kidney transplantation.

Athersys, Inc. announced that it intends to offer and sell shares of its common stock and warrants to purchase common stock, subject to market and other conditions, in a public offering.